Midatech to Present at Rodman & Renshaw Conference

2 September 2015

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech Pharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference

Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announced that Dr. Jim Phillips, Chief Executive Officer, will present at the 17th Annual Rodman & Renshaw Global Investment Conference.

Dr. Phillips is scheduled to present on Thursday, September 10th 2015, at 5:05 p.m. Eastern Time in Astor Suite A (2nd floor) at the St. Regis Hotel in New York City.

A live audio webcast of the presentation will be available to be accessed at http://wsw.com/webcast/rrshq25/mtph or from Midatech's website in the Media, Events section. An archived version of the webcast will be available for 90 days.

- Ends -

For more information, please contact:

Midatech Pharma plc

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Tel: +44 (0)20 7886 2500

Corporate Finance

Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith

Broking

Tom Salvesen

Consilium Strategic Communications

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

[email protected]

Rx Communications Group

Steve Silver

Tel: 917-322-2569

[email protected]

About Midatech Pharma PLC

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. These diseases include diabetes, rare cancers including brain (glioblastoma), ovarian, liver and pancreatic cancer and neurological/ophthalmologic conditions.

Midatech's strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

All of Midatech's product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery ('right place') and controlled release ('right time') of existing drugs. These technologies are provided through its wholly-owned subsidiaries, Midatech and Q Chip (acquired in 2014).

Midatech's core platform is a drug conjugate delivery system based on a patented form of gold nanoparticles (GNP) combined with existing drugs for the safe and targeted release of therapeutic payloads at specific organs, cells or sites of disease.

The Group's second platform is a sustained release technology acquired with Q Chip that involves the consistent and precise encapsulation of active drug compounds within polymer microspheres enabling their release into the body in a highly controlled manner over a prolonged period of time.

Midatech announced the proposed acquisition of DARA BioSciences Inc., (NASDAQ: DARA), an oncology supportive care pharmaceutical company, in June 2015. The acquisition will add an oncology-focused commercial platform and products in the US.

The Group is headquartered near Oxford, UK, with a nanoparticle manufacturing operation in Bilbao, Spain and an R&D facility in Cardiff, UK.

For further company information see: www.midatechgroup.com.